Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (CDMO) and an immunotherapy development platform, has entered into securities purchase and warrant inducement agreements with an existing institutional investor. The transactions are expected to generate approximately $4 million in aggregate gross proceeds, according to the company.
The private placement includes 2,458,334 American Depositary Shares (ADSs), or pre-funded warrants in lieu thereof, along with warrants to purchase up to 3,687,501 additional ADSs. The combined purchase price is set at $1.20 per ADS and accompanying warrants. Separately, under the warrant inducement agreement, the investor will immediately exercise existing warrants covering 879,194 ADSs at a reduced exercise price of $1.20 per ADS and receive new warrants to purchase up to 1,318,791 ADSs. The newly issued Series A-1 warrants will be immediately exercisable at $1.20 per ADS and have five-year terms. The transactions are expected to close on or about Oct. 15, 2026, subject to customary conditions.
Scinai plans to use the net proceeds, together with existing cash resources, to expand its CDMO platform, advance customer programs, and continue selective investment in its immunotherapy pipeline. The company’s pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. Its CDMO subsidiary, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. A.G.P./Alliance Global Partners is serving as sole placement agent for the transactions.
The financing underscores Scinai’s dual strategy of generating near-term revenue through its CDMO services while investing in long-term immunotherapy development. The additional capital is expected to support the expansion of manufacturing capabilities and the advancement of customer programs, which could strengthen the company’s position in the competitive biopharmaceutical services market. For investors, the transaction provides a clearer picture of Scinai’s funding strategy and its commitment to both business segments.
For more details, the full press release can be viewed at https://ibn.fm/eUtYO. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. The announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. IBN’s services include wire distribution via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. Terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
